Biocon has launched KRABEVA, a biosimilar Bevacizumab, in India. It is used for treating patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers, in India.

As per Arun Chandavarkar, CEO and joint MD, Biocon, “We believe KRABEVA will be an important addition to oncology portfolio of novel biologics as well as biosimilars, which are making a significant impact in the realm of cancer care in India.”

Further, KRABEVA is been provided to patients at an MRP of Rs.24,000 for 100 mg / 4 ml vials and Rs.39,990 for 400 mg / 16 ml vials.

Read EquityPandit’s Technical Analysis on Nifty Pharma